Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report

Miriam Champer, Devin Miller, Dennis Yi-Shin Kuo

Research output: Contribution to journalArticle

Abstract

Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

Original languageEnglish (US)
Pages (from-to)26-28
Number of pages3
JournalGynecologic Oncology Reports
Volume28
DOIs
StatePublished - May 1 2019

Fingerprint

Ovarian Neoplasms
Mutation
Therapeutics
Neoplasms
trametinib
Drug Therapy

Keywords

  • Low-grade serous ovarian cancer
  • MEK-inhibitor
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation : A case report. / Champer, Miriam; Miller, Devin; Kuo, Dennis Yi-Shin.

In: Gynecologic Oncology Reports, Vol. 28, 01.05.2019, p. 26-28.

Research output: Contribution to journalArticle

@article{8fcb4e640c1247efbd952860e95db8dd,
title = "Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report",
abstract = "Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.",
keywords = "Low-grade serous ovarian cancer, MEK-inhibitor, Targeted therapy",
author = "Miriam Champer and Devin Miller and Kuo, {Dennis Yi-Shin}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.gore.2019.01.007",
language = "English (US)",
volume = "28",
pages = "26--28",
journal = "Gynecologic Oncology Case Reports",
issn = "2211-338X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation

T2 - A case report

AU - Champer, Miriam

AU - Miller, Devin

AU - Kuo, Dennis Yi-Shin

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

AB - Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

KW - Low-grade serous ovarian cancer

KW - MEK-inhibitor

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85061345638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061345638&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2019.01.007

DO - 10.1016/j.gore.2019.01.007

M3 - Article

AN - SCOPUS:85061345638

VL - 28

SP - 26

EP - 28

JO - Gynecologic Oncology Case Reports

JF - Gynecologic Oncology Case Reports

SN - 2211-338X

ER -